If Kevetrin ends up with good clinical evidence of p53 pathway modulation, it should have a value surpassing Loxo Oncology (acknowledging that we don't have full claim to K royalties...).
This OC Phase 2A is a good step in that direction. (Should have been done years ago, but water under the bridge, of course.) Looking forward to results.
Sox, was there a discussion I missed about the Galera OM FDA2b results looking pretty good. AS I recall you mentioned this upcoming trial in long research update you did on KarinCA's message board.
News 
Market Data 
Discover 
AI
